82-3754

Theralase™ Technologies Inc. Photo-Dynamic Therapy

3080 YONGE STREET • SUITE 5004 • BOX 60 • TORONTO • ONTARIO • CANADA • M4N 3N1
Telephone (416) 368-4440 • Telecopier (416) 865-1382
e-mail:theralase@atlantor.com

05013593

SEC MAIL PROCESSING RECEIVED DEC 27 2005 WASH. D.C. 203 SECTION

PRESS RELEASE

FOR IMMEDIATE RELEASE:

SUBJECT: **Theralase Technologies Inc. Announces U.S. Patent Issued on Proprietary Cancer Therapy Technology**

Toronto; 12 December 2005 -- **Theralase Technologies Inc. (TSXV : TLT & OTC BB : TLTFF)** announced that U.S. Patent No. 6,962,910 has been issued on the metallic complexes employed in the Company's proprietary photo-dynamic cancer therapy research program. The proprietary metallic complexes, which are sub-dermally injected to specifically target cancerous growths, are then activated by the Theralase laser-generated light energy to attack and destroy the tumours. The new patent is subject to the Company's collaboration with Virginia Tech of Blacksburg, Virginia under a long term Technology License Agreement which extends for 20 years following the expiry of the last patent issued under the agreement.

Theralase, in collaboration with Virginia Tech and Toronto's renowned University Health Network cancer research facilities, will commence clinical evaluation of the proprietary metallic compounds in early 2006. If the pending clinical evaluations successfully demonstrate the safety and efficacy of the patented metallic complexes, when laser-activated during small and large animal clinical trials, subsequent human testing is programmed to lead to commercialization of the joint technologies.

Theralase Technologies Inc. designs, develops, manufactures and sells leading edge, proprietary, innovative, higher-powered, super-pulsed therapeutic laser equipment employed in a wide range of photo-dynamic medical therapy applications. The Theralase technology platform targets several diverse healthcare sectors -- firstly, for non-invasive pain management, control and therapy applied to treat musculo-skeletal arthritic and rheumatologic disorders -- secondly, to bio-stimulate and accelerate wound care and healing, including bone fracture regeneration, and for osteoporosis conditions -- and thirdly, combining proprietary metallic complexes with photo-dynamic lasers to attack specifically-targeted cancerous growths.

- 30 -

For Further Information -- Contact:

Roger White; President and CEO; Tel. (905) 947-8455; or
S. Donald Moore; Chairman; Tel. (416) 368-4440

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the contents of this release.

PROCESSED
JAN 03 2006
THOMSON FINANCIAL